As of 2024-12-15, the EV/EBITDA ratio of C4 Therapeutics Inc (CCCC) is -2.17. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CCCC's latest enterprise value is 249.54 mil USD. CCCC's TTM EBITDA according to its financial statements is -115.13 mil USD. Dividing these 2 quantities gives us the above CCCC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.6x - 16.8x | 15.9x |
| Forward P/E multiples | 15.2x - 21.1x | 15.5x |
| Fair Price | (23.95) - (26.55) | (24.76) |
| Upside | -646.7% - -706.3% | -665.3% |
| Date | EV/EBITDA |
| 2024-12-13 | -2.17 |
| 2024-12-12 | -2.13 |
| 2024-12-11 | -2.37 |
| 2024-12-10 | -2.12 |
| 2024-12-09 | -2.05 |
| 2024-12-06 | -2.19 |
| 2024-12-05 | -1.87 |
| 2024-12-04 | -1.88 |
| 2024-12-03 | -1.97 |
| 2024-12-02 | -2.12 |
| 2024-11-29 | -2.27 |
| 2024-11-27 | -2.27 |
| 2024-11-26 | -2.05 |
| 2024-11-25 | -2.17 |
| 2024-11-22 | -2.09 |
| 2024-11-21 | -1.94 |
| 2024-11-20 | -1.97 |
| 2024-11-19 | -2.03 |
| 2024-11-18 | -2.06 |
| 2024-11-15 | -2.12 |
| 2024-11-14 | -2.38 |
| 2024-11-13 | -2.63 |
| 2024-11-12 | -2.86 |
| 2024-11-11 | -3.09 |
| 2024-11-08 | -3.20 |
| 2024-11-07 | -3.19 |
| 2024-11-06 | -3.14 |
| 2024-11-05 | -3.22 |
| 2024-11-04 | -3.44 |
| 2024-11-01 | -2.92 |
| 2024-10-31 | -2.75 |
| 2024-10-30 | -2.87 |
| 2024-10-29 | -3.10 |
| 2024-10-28 | -3.16 |
| 2024-10-25 | -3.09 |
| 2024-10-24 | -3.13 |
| 2024-10-23 | -3.19 |
| 2024-10-22 | -3.29 |
| 2024-10-21 | -3.31 |
| 2024-10-18 | -3.38 |
| 2024-10-17 | -3.41 |
| 2024-10-16 | -3.77 |
| 2024-10-15 | -3.34 |
| 2024-10-14 | -3.09 |
| 2024-10-11 | -2.83 |
| 2024-10-10 | -2.73 |
| 2024-10-09 | -2.58 |
| 2024-10-08 | -2.63 |
| 2024-10-07 | -2.64 |
| 2024-10-04 | -2.78 |